Replies to post #516502 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

You are elegantly ignoring that at the time of the rejection, a large Phase 3 trial (TRAILBLAZER-ALZ 2) was already ongoing and close to readout.

Lilly explicitly stated the Phase 3 readout was expected mid-2023 and would support a full approval filing.

Positive Phase 3 results were announced May 2023 (topline), showing significant slowing of decline.

Anavex have no such provisions in place and that is a problem. Do I have say again what I have said already too many times?